-
Huibaoyuan Bio's new anti-cancer drug xylazine obtained clinical trial approval from the U.S. FDA
Time of Update: 2021-11-05
This study aims to evaluate the overall survival benefit and safety of JP001 combined with standard radiotherapy and chemotherapy for newly diagnosed GBM patients .
Combined with surgical resection and radiotherapy, the median survival can be extended to 12.
-
Johnson & Johnson's EGFR/c-Met dual antibody, the first new drug for specific mutations in lung cancer, was approved by the FDA for marketing
Time of Update: 2021-06-01
On May 21, the FDA issued an announcement to accelerate the approval of Johnson & Johnson's Rybrevant (amivantamab-vmjw) for patients with metastatic non-small cell lung cancer (NSCLC) who have advanced EGFR exon 20 insertion mutations after platinum-based chemotherapy.
-
O Drug New Surprise: US FDA Approves Immunotherapy for First-line Treatment of Advanced Gastric Cancer for the First Time
Time of Update: 2021-04-22
April 16, the US Food and Drug Administration Bureau ( the FDA when) the approval of Bristol-Myers Squibb PD-1 monoclonal antibody inhibitors Carolina Wu (Opdivo, nivolumab) with certain types of chemotherapy used in combination, for advanced or metastaticInitial treatment of patients with gastric cancer , gastroesophageal junction cancer and esophageal adenocarcinoma.
-
EGFR mutation lung cancer first-line treatment of new options! Pfizer's second-generation targeted cancer drug Vizimpro has been approved by the FDA,..
Time of Update: 2021-02-06
OS data from key head-to-head III studies are very encouraging, with the mid-OS in patients treated with Vizimpro's EGFR-activated mutant NSCLC approaching 3 years, a significant improvement over the current clinical first-line treatment, Iressa.
-
The FDA granted Kangfang BioPD-1/CTLA-4 dual anti-new drug (AK104) rapid approval for treatment of advanced cervical cancer.
Time of Update: 2020-09-04
August 12, Kangfang Bio announced that its core independently developed, the world's first new cancer immunotherapy dual-specific antibody drug PD-1/CTLA-4 (AK104) for the treatment of advanced cervical cancer has been granted fast-track approval channel (FTD) by the U.S. Food and Drug Administration (FDA).
-
FDA approves new drug for small cell lung cancer! Green Leaf Pharmaceuticals has interests in China.
Time of Update: 2020-08-01
Green Leaf Pharmaceuticals signed a licensed research and development cooperation agreement with PharmaMar in April 2019 for Lurbinectedin, which was in Phase III, to acquire exclusive rights to the development and commercialization of the drug in China, including all indications of small cell lung cancer.
-
FDA approves new drug for advanced kidney cancer
Time of Update: 2020-07-08
the U.S Food and Drug Administration approved a new drug Wednesday to extend the survival of patients with advanced kidney cancer The drug, called Torisel, is manufactured by Wyeth Pharmaceuticals
-
FDA approves new drug for small cell lung cancer! Green Leaf Pharmaceuticals has interest in China
Time of Update: 2020-06-25
, June 17 (Xinhua) -- Jazz Pharmaceuticals/PharmaMar announced on June 15 that the FDA has accelerated the approval of Zepzelca (lurbinectedin) for the treatment of metastatic small cell lung cancer,
-
FDA approves new cancer drug Copiktra (duvelisib) for use in CLL and SLL adult patients
Time of Update: 2020-06-11
lymphoma is the most common type of blood cancer The three types of blood cancer treated by Copiktra are inert non-Hodgkin lymphoma (indolent non-Hodgkin lymphoma) yesterday (September 25), the U.S
-
FDA approves Novartis' new oral targeted cancer drug Kisqali for treatment of patients with advanced or metastatic breast cancer
Time of Update: 2020-06-11
recently, Swiss Pharmaceutical scoundrel Novartis announced that the U.S Food and Drug ( FDA () has approved the new oral targeting anti-cancer drug Kisqali (ribociclib) for the treatment of pat
-
FDA approves Pfizer's new cancer drug Talazoparib for treatment of breast cancer patients
Time of Update: 2020-06-11
breast cancer is one of the most important types of cancer that threaten a woman's life Women who carry genetic BRCA1 or BRCA2 mutations have a 65 percent risk of developing breast cancer before age
-
FDA approves new drug application for anti-cancer drug Xtandi
Time of Update: 2020-06-11
recently Pfizer and partner Astellas jointly announced that the U.S Food Drug ( FDA () has approved a supplementtoe new drug (application, expanding its current indications to include non-metas
-
FDA accelerates approval of new indications for targeted cancer drug Venetoxta
Time of Update: 2020-06-10
, AbbVie and partner Roche announced that the Authority of the of food and drugs (http:// ( FDA (http:// ) has accelerated the approval of a new indication of the anti-cancer drug Venetoxta, a l
-
PD-1 new drug Balstilimab single drug for cervical cancer approved by FDA fast-track
Time of Update: 2020-05-30
Agenus, a biopharmaceutical company dedicated to the development of immuno-oncology drugs, announced that the FDA has granted its PD-1 inhibitor balstilimab fast-track eligibility for the treatment of
-
Green leaf pharmaceutical new prostate cancer drug approved by FDA
Time of Update: 2020-04-03
Green leaf Pharmaceutical (02186 HK) announced that the group's in-process product, geserelin acetate sustained-release microspheres for injection (ly01005), has been approved by the U.S Food and Drug
